

## Erratum to: Long-term safety and efficacy of Omnitrope<sup>®</sup> in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults study

D. Ferone<sup>1</sup> · E. Profka<sup>2</sup> · V. Gasco<sup>3</sup> · M. R. Ambrosio<sup>4</sup> · A. Colao<sup>5</sup> · C. Di Somma<sup>6</sup> · E. Puxeddu<sup>7</sup> · G. Arnaldi<sup>8</sup> · C. Pagano<sup>9</sup> · E. Zecchi<sup>10</sup> · A. Pietropoli<sup>11</sup> · P. Beck-Peccoz<sup>12</sup>

Published online: 18 April 2017

© Italian Society of Endocrinology (SIE) 2017

**Erratum to: J Endocrinol Invest**  
DOI [10.1007/s40618-016-0604-8](https://doi.org/10.1007/s40618-016-0604-8)

Unfortunately, the Figs. 1 and 3 were switched and wrongly published in the original version. The correct Figs. 1 and 3 and the respective caption are given in the following page.

The original version is also updated.

---

The online version of the original article can be found under doi:[10.1007/s40618-016-0604-8](https://doi.org/10.1007/s40618-016-0604-8).



---

✉ D. Ferone  
ferone@unige.it

- <sup>1</sup> Endocrinology Unit, Department of Internal Medicine and Medical Specialties (DiMI), Center of Excellence for Biomedical Research (CEBR), IRCCS AOU San Martino-IST, University of Genova, Viale Benedetto XV, 6, 16132 Genova, Italy
- <sup>2</sup> Endocrinology and Metabolic Diseases Unit, Department of Clinical Sciences and Community Health, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Cà Granda Ospedale Maggiore Policlinico, University of Milano, Milan, Italy
- <sup>3</sup> Endocrinology, Diabetes and Metabolism, Department of Medical Science, Città della Salute e della Scienza di Torino, University of Torino, Turin, Italy
- <sup>4</sup> Section of Endocrinology and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy
- <sup>5</sup> Department of Clinical Medicine and Surgery, University Federico II of Napoli, Naples, Italy

- <sup>6</sup> Institute of Diagnostic and Nuclear Research, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico SDN, Naples, Italy
- <sup>7</sup> Veterinary and Forensic Biotechnological Sciences Department of Medicine Section, Internal Medicine, Endocrine and Metabolic Sciences, University of Perugia, Perugia, Italy
- <sup>8</sup> Clinica di Endocrinologia e Malattie del Metabolismo, Ospedali Riuniti di Ancona, Ancona, Italy
- <sup>9</sup> Department of Medicine, Internal Medicine 3, University of Padova, Padua, Italy
- <sup>10</sup> Sandoz S.p.A., Origgio, VA, Italy
- <sup>11</sup> Hexal AG, Holzkirchen, Germany
- <sup>12</sup> Endocrinology and Diabetology Unit, Medical Sciences Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Cà Granda Ospedale Maggiore Policlinico, Milan, Italy

**Fig. 1** Change in **a** fasting glucose and **b** glycosylated haemoglobin (HbA1c) in the total safety analysis set over the study period



**Fig. 3** Change in **a** insulin-like growth factor-1 (IGF-1) and **b** IGF-1 standard deviation scores (IGF-1 SDS) in treatment naïve patients included in the efficacy analysis set over the study period

